KMTS (Kestra Medical Technologies) ROC %: -156.26% (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
10 GF Score
Price $24.03
! 3 Warning Signs
View Full Analysis

What is Kestra Medical Technologies ROC %?

Kestra Medical Technologies KMTS -0.87% 10 ROC % is -156.26% as of Apr. 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Kestra Medical Technologies's annualized return on capital (ROC %) for the quarter that ended in Apr. 2026 was -156.26%.

As of today (2026-07-15), Kestra Medical Technologies's WACC % is 10.78%. Kestra Medical Technologies's ROC % is -254.50% (calculated using TTM income statement data). Kestra Medical Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Kestra Medical Technologies  (NAS:KMTS) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Kestra Medical Technologies's WACC % is 10.78%. Kestra Medical Technologies's ROC % is -254.50% (calculated using TTM income statement data). Kestra Medical Technologies earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Kestra Medical Technologies ROC % Related Terms


Kestra Medical Technologies ROC % Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies ROC % Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24 Apr25
ROC %
-1,359.25 -867.13 -308.73 -202.66 -245.93

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -407.98 -227.16 -226.68 -222.61 -156.26
KMTS
10GF Score
Kestra Medical Technologies Ltd KMTS
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies ROC % Calculation

Kestra Medical Technologies's annualized Return on Capital (ROC %) for the fiscal year that ended in Apr. 2025 is calculated as:

ROC % (A: Apr. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Apr. 2024 ) + Invested Capital (A: Apr. 2025 ))/ count )
=-106.378 * ( 1 - 0% )/( (37.236 + 49.276)/ 2 )
=-106.378/43.256
=-245.93 %

where

Invested Capital(A: Apr. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=295.744 - 29.117 - ( 237.595 - max(0, 37.977 - 255.328+237.595))
=49.276

Kestra Medical Technologies's annualized Return on Capital (ROC %) for the quarter that ended in Apr. 2026 is calculated as:

ROC % (Q: Apr. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2026 ) + Invested Capital (Q: Apr. 2026 ))/ count )
=-157.376 * ( 1 - 0% )/( (65.289 + 136.137)/ 2 )
=-157.376/100.713
=-156.26 %

where

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=379.342 - 42.921 - ( 291.321 - max(0, 42.931 - 314.063+291.321))
=65.289

Invested Capital(Q: Apr. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=358.465 - 50.341 - ( 196.434 - max(0, 50.372 - 222.359+196.434))
=136.137

Note: The Operating Income data used here is four times the quarterly (Apr. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -156.26% mean?
Kestra Medical Technologies (KMTS) has a ROC % of -156.26% as of Apr. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' ROC % too high?
Kestra Medical Technologies' current ROC % is -156.26%. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' ROC % compare to ATRC and STAA?
Kestra Medical Technologies' ROC % of -156.26% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Medical Devices & Instruments company?
The median ROC % among Medical Devices & Instruments companies is 1.27, based on 847 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current ROC % is -156.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current ROC % of -156.26%. The current ROC % is -156.26%. Kestra Medical Technologies' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current ROC % is -156.26% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score

Get the complete analysis for KMTS

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.03
Price